Perspectives on Enquiry & Evidence

Clinical researchers, seeking to understand the statistical benefits of a common Phase 2 oncology design, now have a..

In most instances of blinded sample size re-estimation, the timing of the interim analysis that determines whether the..

Hello! I’m delighted to pen my inaugural blog post here as Cytel’s Chief Medical Officer. In this series, we’ll explore..

In our previous blog, “Remote Working Arrangement – How to get it right?”, we talked about how the need for social..

An extraordinary amount of global research is underway as the COVID-19 pandemic continues to evolve and spread..

Cytel's team of oncology trial design and advanced analytics experts are hosting a series of complimentary webinars..

Cytel is hosting a webinar, “A Clinician’s Perspective on Cancer Drugs Development”, on April 28, 2020. Our speaker,..

 

In honor of Rare Disease Day 2019 we share a new Cytel podcast featuring Cytel Strategic Consultant Ursula Garczarek..